Aspergillus fumigatus is a significant filamentous fungus known for causing severe infections and allergic reactions, particularly in immunocompromised individuals.
One of its key proteins, Asp f3, functions as an allergen, a virulence factor, and a scavenger of reactive oxygen species (ROS).
Asp f3 also helps the fungus thrive in low-iron conditions by compensating for the loss of iron-dependent antioxidant enzymes, crucial for its survival and virulence.
While initially believed to protect the fungus from immune cell killing, experiments showed Asp f3-depleted fungi were killed as effectively as wild types by human immune cells.
Asp f3's role in iron homeostasis and its potential as a vaccine candidate against aspergillosis highlight its importance. Studies have demonstrated the recombinant Asp f3 (rAsp f3) protein-based vaccine's efficacy in preventing invasive pulmonary aspergillosis in immunosuppressed mice, primarily through CD4+ T cells.
Despite its vital role, Asp f3 alone is not sufficient for diagnosing ABPA due to low sensitivity and cross-reactivity, but it remains a crucial target for further research and therapeutic development.
Aspergillus fumigatus is a species of filamentous fungus that plays important ecological roles but can also cause serious infections in humans.
Aspergillus fumigatus is a leading cause of aspergillosis, an infection ranging from allergic reactions to invasive pulmonary disease, particularly affecting immunocompromised individuals.
Early diagnosis, species identification, and appropriate antifungal therapy are crucial for effective treatment.
Aspergillus fumigatus is part of the genus Aspergillus, which includes over 250 species, many of which are pathogenic.
This species is characterized by bluish-green conidial heads and a high thermotolerance, allowing it to thrive in diverse environments, from soil and compost to decaying vegetation. It is highly prevalent due to its resilience and ability to produce numerous secondary metabolites.
A. fumigatus possesses several virulence factors, such as conidial melanin and gliotoxin, which help it evade host defenses.
It can grow at body temperature and survive in the host's nutrient-limited environment, making it a formidable pathogen in immunocompromised patients.
The fungus’ ability to produce ascospores, virulence factors, and its high thermotolerance contribute to its virulence.
Infections by A. fumigatus primarily affect the lungs but can disseminate to other organs, especially in immunocompromised patients.
The central nervous system is another common site highly affected by A. fumigatus. [10.]
Conditions include invasive aspergillosis (IA), allergic bronchopulmonary aspergillosis (ABPA), and chronic pulmonary aspergillosis. IA has a high fatality rate and is particularly severe in patients with weakened immune systems.
Acute invasive aspergillosis is a serious infection in immunocompromised patients, characterized by rapid progression, often resulting in high fatality rates.
In contrast, chronic Aspergillus infections typically affect patients with some degree of immune suppression and underlying lung diseases like chronic obstructive pulmonary disease (COPD), as well as those on long-term corticosteroids. It progresses slowly, leading to lung tissue damage or sinus problems over time.
Allergic aspergillosis, including Allergic Bronchopulmonary Aspergillosis (ABPA) and Allergic Fungal Sinusitis, are caused by type 1 or type 3 hypersensitivity reactions.
ABPA, a pulmonary disease caused by hypersensitivity reactions to Aspergillus fumigatus allergens, commonly occurs in asthmatic and cystic fibrosis patients and causes bronchial obstruction, productive cough, wheezing, chest pain, fever, and malaise.
Allergic fungal sinusitis causes inflammation and obstruction without tissue invasion.
Accurate diagnosis involves a combination of morphological and genetic analyses, with galactomannan and (1,3)-β-D-glucan assays being commonly used. Certain antigens and virulence factors such as A. fumigatus Asp f 1 can also be tested.
Voriconazole is the preferred treatment for IA, supported by guidelines from the Infectious Diseases Society of America. [11.] Timely initiation of antifungal therapy is critical for improving patient outcomes.
Virulence factors of Aspergillus species include:
Biofilms protect Aspergillus from host defenses and antifungal treatments, promoting persistent and chronic infections, especially in immune-compromised individuals. [7.]
Lipases degrade lipids, aiding in nutrient acquisition and tissue invasion by breaking down host cell membranes. [7.]
α-Amylase breaks down carbohydrates, providing energy and aiding in colonization of host tissues. [7.]
Pectinases degrade pectin, a polysaccharide found in plant cell walls, facilitating the invasion of plant-derived substrates. [7.]
Proteinases degrade proteins, helping the fungus to invade host tissues and evade immune responses. [7.]
Phospholipases break down phospholipids in cell membranes, aiding in host cell lysis and tissue penetration. [7.]
Haemolysins lyse red blood cells, releasing iron and other nutrients vital for fungal growth and survival in the host. [7.]
Catalases (Cat1p and Cat2p) and superoxide dismutases (MnSOD and Cu, ZnSOD) produced by Aspergillus neutralize the immune system’s offenses. [9.]
These virulence factors confuse and impede the immune response, while promoting cell invasion and death. [6.]
Asp f 3 is part of a family of ribotoxins produced by Aspergillus species. They are potent inhibitors of protein synthesis in eukaryotic cells, as well as potent stimulators of allergenicity. The family of ribotoxins includes mitogillin, restrictocin, and α-sarcin, and Asp f1 to Asp f23. [6.]
Asp f3 is a protein found in the fungus Aspergillus fumigatus, which can cause allergic reactions and serious infections. The Asp f 3 protein acts as an allergen, a virulence factor that helps the fungus infect hosts, and a scavenger of harmful reactive oxygen species (ROS), all of which enable the fungus to thrive inside other animals. [2., 3.]
Initially, it was believed that Asp f3 protected the fungus from being killed by immune cells. However, experiments showed that Asp f3-depleted fungi (mutants) were killed just as effectively by human immune cells as the wild type.
These mutants showed significant growth problems in low-iron conditions, explaining why they were less virulent (able to cause disease) in mice.
Asp f3 helps the fungus grow when iron is scarce by compensating for the loss of other iron-dependent antioxidant enzymes. The fungus has two similar proteins, Af3l1 and Af3l2, but only Af3l1 also helps in low-iron conditions.
When the iron acquisition repressor gene SreA was inactivated, it partially made up for the lack of Asp f3, linking Asp f3’s role to iron homeostasis.
Asp f3 is essential for the fungus to overcome the host's defenses that limit iron availability during infection.
In experiments, providing extra iron restored the ability of the Asp f3 mutants to cause disease in mice. This shows that Asp f3 is crucial for the fungus to thrive under iron-limited conditions and resist oxidative stress, making it a potential target for treatments against A. fumigatus infections.
Aspergillus fumigatus is a significant fungal pathogen that can cause severe infections and allergic reactions.
One of its key proteins, Asp f3, has multiple roles, including functioning as an allergen, a scavenger of reactive oxygen species (ROS), and a virulence factor.
Recent research has explored its potential as a vaccine candidate against aspergillosis, a serious fungal disease that particularly affects patients undergoing hematopoietic cell transplantation.
The recombinant Asp f3 (rAsp f3) protein-based vaccine has shown promise in preventing invasive pulmonary aspergillosis in immunosuppressed mice. [3.] In these studies, the vaccine protected cortisone acetate (CA)-immunosuppressed mice through the action of CD4+ T cells.
In CA-immunosuppressed mice, which are highly susceptible to aspergillosis, the rAsp f3 vaccine significantly improved survival rates. The vaccine's protective effect in these mice was evident as their lungs were largely free of fungal burden, unlike in non-vaccinated mice where the infection was more severe. [3.]
The study found that neutrophils, while essential for innate immune protection in healthy hosts, were not the main effectors for the rAsp f3 vaccine's protection in immunosuppressed hosts.
Instead, macrophages likely represent the crucial effector cells. This highlights the importance of Asp f3 in overcoming iron limitation during infection and suggests its potential as a therapeutic target for preventing aspergillosis.
Further research is needed to fully understand the mechanisms by which the rAsp f3 vaccine confers protection and to refine its application in clinical settings.
A. fumigatus Asp f 3 may be used as a biomarker for the diagnosis and monitoring of Aspergillus-related diseases, such as allergic bronchopulmonary aspergillosis (ABPA), severe asthma with fungal sensitization (SAFS), and invasive aspergillosis (IA), although it is not commonly assessed.
Testing for Asp f3-specific antibodies alone is not sufficient to diagnose ABPA due to low sensitivity and cross-reactivity, as was demonstrated in a study of cystic fibrosis patients. [6.]
Combining tests for multiple recombinant allergens (Asp f1, f2, f3, f4, f6) and evaluating various antibody isotypes may improve diagnostic accuracy. [6.]
The detection of A. fumigatus Asp f 3-specific IgE antibodies in serum or other biological fluids can indicate exposure to A. fumigatus and assist in the diagnosis of these conditions.
Often, blood tests are run to assess for antibodies against the infectious agent A. fumigatus.
Sputum or bronchoalveolar lavage may also be assessed for the presence of Aspergillus fumigatus.
Blood tests typically require a venipuncture.
While special preparation may not be required, it is essential to consult with the ordering provider prior to sample collection.
A. fumigatus Asp f 3 is a virulence factor associated with infection by the A. fumigatus fungus. Ideal levels are undetectable, or extremely low, in the absence of symptoms.
The presence of symptoms, even with low levels on testing, may signify the need for further assessment including additional attesting for the presence of other molds, fungi, mycotoxins, or infectious agents.
Elevated levels of A. fumigatus may indicate an allergic sensitization, or an active infection. An infection signals a need for eradication of the A. fumigatus organism; additional assessment for the presence of co-infections may be warranted.
An individual with elevated levels of this biomarker may need additional assessment of immune function and may require additional immune support.
Click here to compare testing options and order tests for Aspergillus fumigatus levels.
[1.] Arruda LK, Platts-Mills TA, Fox JW, Chapman MD. Aspergillus fumigatus allergen I, a major IgE-binding protein, is a member of the mitogillin family of cytotoxins. J Exp Med. 1990 Nov 1;172(5):1529-32. doi: 10.1084/jem.172.5.1529. PMID: 2230656; PMCID: PMC2188668.
[2.] Brantl V, Boysen JM, Yap A, et al. Peroxiredoxin Asp f3 Is Essential for Aspergillus fumigatus To Overcome Iron Limitation during Infection. MBio. 2021;12(4). doi:https://doi.org/10.1128/mbio.00976-21
[3.] Diaz-Arevalo D, Ito JI, Kalkum M. Protective Effector Cells of the Recombinant Asp f3 Anti-Aspergillosis Vaccine. Front Microbiol. 2012 Aug 22;3:299. doi: 10.3389/fmicb.2012.00299. PMID: 23024640; PMCID: PMC3441197.
[4.] Davies G, Singh O, Prattes J, Hoenigl M, Sheppard PW, Thornton CR. Aspergillus fumigatus and Its Allergenic Ribotoxin Asp f I: Old Enemies but New Opportunities for Urine-Based Detection of Invasive Pulmonary Aspergillosis Using Lateral-Flow Technology. J Fungi (Basel). 2020 Dec 31;7(1):19. doi: 10.3390/jof7010019. PMID: 33396482; PMCID: PMC7823411.
[5.] Kurup VP, Banerjee B, Murali PS, Greenberger PA, Krishnan M, Hari V, Fink JN. Immunodominant peptide epitopes of allergen, Asp f 1 from the fungus Aspergillus fumigatus. Peptides. 1998;19(9):1469-77. doi: 10.1016/s0196-9781(98)00113-2. PMID: 9864052.
[6.] Kurup VP, Knutsen AP, Moss RB, Bansal NK. Specific antibodies to recombinant allergens of Aspergillus fumigatus in cystic fibrosis patients with ABPA. Clin Mol Allergy. 2006 Jul 21;4:11. doi: 10.1186/1476-7961-4-11. PMID: 16859543; PMCID: PMC1550719.
[7.] Raksha, Singh G, Urhekar AD. Virulence Factors Detection in Aspergillus Isolates from Clinical and Environmental Samples. J Clin Diagn Res. 2017 Jul;11(7):DC13-DC18. doi: 10.7860/JCDR/2017/24055.10211. Epub 2017 Jul 1. PMID: 28892890; PMCID: PMC5583800.
[8.] Raval KM, Ghormade V, Rajamohanan PR, Choudhary H, Rudramurthy SM, Chakrabarti A, Paknikar K. Development of a nano-gold immunodiagnostic assay for rapid on-site detection of invasive aspergillosis. J Med Microbiol. 2019 Sep;68(9):1341-1352. doi: 10.1099/jmm.0.001040. PMID: 31355743.
[9.] Rementeria A, López-Molina N, Ludwig A, Vivanco AB, Bikandi J, Pontón J, Garaizar J. Genes and molecules involved in Aspergillus fumigatus virulence. Rev Iberoam Micol. 2005 Mar;22(1):1-23. doi: 10.1016/s1130-1406(05)70001-2. PMID: 15813678.
[10.] Sugui JA, Kwon-Chung KJ, Juvvadi PR, Latgé JP, Steinbach WJ. Aspergillus fumigatus and related species. Cold Spring Harb Perspect Med. 2014 Nov 6;5(2):a019786. doi: 10.1101/cshperspect.a019786. PMID: 25377144; PMCID: PMC4315914.
[11.] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2008;46(3):327-360. doi:https://doi.org/10.1086/525258